Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.

Slot S, Raymakers RAP, Schaap N, Span LFR, Koene HR, Kersting S, Te Boekhorst PAW, Westerman M, Schouten HC, Zweegman S.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):624-634. doi: 10.1016/j.clml.2019.07.005. Epub 2019 Jul 15.

PMID:
31427260
2.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
3.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

4.

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Franssen LE, Nijhof IS, Bjorklund CC, Chiu H, Doorn R, van Velzen J, Emmelot M, van Kessel B, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Sonneveld P, Zweegman S, Lokhorst HM, Thakurta A, Qian X, Mutis T, van de Donk NWCJ.

Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131. eCollection 2018 Sep 21.

5.

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.

Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA.

Anticancer Drugs. 2018 Sep;29(8):791-801. doi: 10.1097/CAD.0000000000000648.

PMID:
29846248
6.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, Klein SK, Ren Y, Wang M, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Leguit RJ, Sonneveld P, Zweegman S, Lokhorst H, Mutis T, Thakurta A, Qian X, van de Donk NWCJ.

Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15. No abstract available.

7.

Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.

Persoon S, ChinAPaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ.

PLoS One. 2017 Jul 20;12(7):e0181313. doi: 10.1371/journal.pone.0181313. eCollection 2017.

8.

Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia.

Tjon JM, de Groot MR, Sypkens Smit SMA, de Wreede LC, Snijders TJF, Koene HR, Meijer E, Raaijmakers MHG, Schaap M, Raymakers R, Zeerleder SS, Halkes CJM.

Br J Haematol. 2018 Feb;180(3):459-462. doi: 10.1111/bjh.14372. Epub 2016 Oct 7. No abstract available.

PMID:
27714765
9.

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.

PMID:
27647864
10.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group.

Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25. No abstract available.

11.

Keeping venomous snakes in the Netherlands: a harmless hobby or a public health threat?

van Genderen PJ, Slobbe L, Koene H, Mastenbroek RD, Overbosch D.

Neth J Med. 2013 Oct;71(8):437-41.

12.

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

Abouyahya I, Alhan C, Westers TM, te Boekhorst PA, Kappers-Klunne MC, Coenen JL, Heyning FH, Huls GA, de Wolf JT, Imholz AL, Koene HR, Veth G, de Kruijf EJ, Muus P, Planken EV, Segeren CM, Vasmel WL, van der Velden AM, Velders GA, Koedam J, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Lymphoma. 2013 Apr;54(4):874-7. doi: 10.3109/10428194.2012.728702. Epub 2012 Sep 28. No abstract available.

PMID:
22971215
13.

Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis.

te Raa GD, Tonino SH, Remmerswaal EB, van Houte AJ, Koene HR, van Oers MH, Kater AP.

Leuk Lymphoma. 2012 Nov;53(11):2321-5. doi: 10.3109/10428194.2012.698277. Epub 2012 Aug 25.

PMID:
22646856
14.

Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.

Dienava-Verdoold I, Marchetti MR, te Boome LC, Russo L, Falanga A, Koene HR, Mertens K, Brinkman HJ.

Thromb Haemost. 2012 Mar;107(3):468-76. doi: 10.1160/TH11-07-0457. Epub 2012 Feb 8.

PMID:
22318644
15.

Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.

Lauw MN, Bus EW, van Wulfften Palthe AF, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ.

Ann Hematol. 2012 Jan;91(1):103-7. doi: 10.1007/s00277-011-1233-0. Epub 2011 Apr 12.

16.

Prevalence of JAK2V617F mutation in women with unexplained recurrent miscarriage.

Kaandorp SP, Lauw MN, van der Schoot CE, Goddijn M, van der Veen F, Koene HR, Biemond BJ, Middeldorp S.

J Thromb Haemost. 2010 Dec;8(12):2837-9. doi: 10.1111/j.1538-7836.2010.04066.x. No abstract available.

17.

[Clinical reasoning and decision-making in practice. A man with hip pain and fever].

Tuinman PR, de Nes LC, Blaauwgeers JL, Koene HR, Peters SH, Hart W.

Ned Tijdschr Geneeskd. 2008 Jul 12;152(28):1560-7. Dutch.

PMID:
18712223
18.

[New treatment methods for autoimmune thrombocytopenia].

Koene HR.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2609-14. Review. Dutch.

PMID:
18161261
19.

Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.

Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, Roos D, de Haas M, Koene HR, Kuijpers TW.

Blood. 2008 Feb 1;111(3):1029-38. Epub 2007 Sep 7.

PMID:
17827395
20.

[From gene to disease; JAK2 and polycythaemia vera].

Koene HR, Biemond BJ, van der Schoot CE.

Ned Tijdschr Geneeskd. 2007 Aug 11;151(32):1784-7. Review. Dutch.

PMID:
17822250
21.

[Systematic diagnosis of erythrocytosis].

de Heer K, Silbermann MH, Koene HR, Biemond BJ, Muller HP, van Oers MH.

Ned Tijdschr Geneeskd. 2007 Aug 11;151(32):1770-6. Review. Dutch.

PMID:
17822247
22.

The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].

van Genderen PJ, Koene HR, Spong K, Overbosch D.

J Travel Med. 2007 Mar-Apr;14(2):92-5. Erratum in: J Travel Med. 2007 May-Jun;14(3):203.

23.

Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights.

Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G.

Neth J Med. 2006 Nov;64(10):356-63. Review.

24.

Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura.

Koene HR.

Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):703-5. Review.

PMID:
16933273
25.

[Clinical reasoning and decision making in practice. A 39-year-old woman with somnolence, hypertension and haemolysis].

van den Born BJ, Koene HR, Koopmans RP, Hart W.

Ned Tijdschr Geneeskd. 2006 Mar 4;150(9):481-8. Dutch.

PMID:
16553046
26.

Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).

Kumpel BM, De Haas M, Koene HR, Van De Winkel JG, Goodrick MJ.

Clin Exp Immunol. 2003 Apr;132(1):81-6.

27.

The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Dekkers PE, ten Hove T, Lauw FN, Koene HR, Lumley P, van Deventer SJ, van der Poll T.

Infect Immun. 2000 May;68(5):3036-9.

28.

Levels of soluble Fc gammaRIII correlate with disease severity in sepsis.

Muller Kobold AC, Zijlstra JG, Koene HR, de Haas M, Kallenberg CG, Tervaert JW.

Clin Exp Immunol. 1998 Nov;114(2):220-7.

29.

The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus.

Koene HR, Kleijer M, Swaak AJ, Sullivan KE, Bijl M, Petri MA, Kallenberg CG, Roos D, von dem Borne AE, de Haas M.

Arthritis Rheum. 1998 Oct;41(10):1813-8.

PMID:
9778222
30.

Clinical value of soluble IgG Fc receptor type III in plasma from patients with chronic idiopathic neutropenia.

Koene HR, de Haas M, Kleijer M, Huizinga TW, Roos D, von dem Borne AE.

Blood. 1998 May 15;91(10):3962-6.

PMID:
9573035
31.

[Immunology in clinical practice. XI. IgG receptors: the role of polymorphism in autoimmune and infectious diseases].

van der Pol WL, Kuijper EJ, Koene HR, de Haas M, Sanders EA, van de Winkel JG.

Ned Tijdschr Geneeskd. 1998 Feb 14;142(7):340-5. Review. Dutch.

PMID:
9562739
32.
34.
35.

Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections.

de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AE, Waaijer JL, Haraldsson A, de Haas M, van Tol MJ.

Blood. 1996 Oct 15;88(8):3022-7.

PMID:
8874200
36.

A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.

de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem Borne AE.

J Immunol. 1996 Apr 15;156(8):2948-55.

PMID:
8609432
37.

NA-phenotype-dependent differences in neutrophil Fc gamma RIIIb expression cause differences in plasma levels of soluble Fc gamma RIII.

Koene HR, de Haas M, Kleijer M, Roos D, von dem Borne AE.

Br J Haematol. 1996 Apr;93(1):235-41.

PMID:
8611467
38.

[The ultimate fate of articles rejected for publication in the Nederlands Tijdschrift voor Geneeskunde].

Koene HR, Overbeke AJ.

Ned Tijdschr Geneeskd. 1994 Dec 3;138(49):2443-6. Dutch.

PMID:
7997300
39.

[The scientific value of society reports in the Nederlands Tijdschrift voor Geneeskunde].

Koene HR, Overbeke AJ.

Ned Tijdschr Geneeskd. 1994 Sep 10;138(37):1868-71. Dutch.

PMID:
7935924
40.

[Use of alternative medical procedures: between hope and fear].

Koene HR, Koene RA.

Ned Tijdschr Geneeskd. 1994 Apr 23;138(17):879-80. Dutch. No abstract available.

PMID:
8183403

Supplemental Content

Support Center